The Priority Review

Tag

Qilu Pharmaceutical

1 story

Stories

  1. Clinical trials

    Qilu Pharmaceutical registers Phase 3 trial of QLS4131 in relapsed or refractory multiple myeloma

    The study, first posted on ClinicalTrials.gov on November 12, 2026, plans to enroll 300 participants and has a planned start date of December 30, 2026. It compares QLS4131 injection with the investigator's choice regimen in participants with relapsed or refractory multiple myeloma.